Vaccine News and Research

Latest Vaccine News and Research

Only 40% of parents will get their child vaccinated against H1N1?

The latest C.S. Mott Children's Hospital National Poll on Children's Health finds only 40 percent of parents indicate they will get their children vaccinated against H1N1 flu -- while 54 percent of parents indicate they will get their children vaccinated against seasonal flu. Among parents who do not plan to get their children vaccinated against H1N1 flu, 46 percent indicate they are not worried about their children getting H1N1 flu, while 20 percent believe H1N1 flu is not serious.

25 Sep 2009

H1N1 influenza pandemic could present a host of medical ethics issues: JCB

The anticipated onset of a second wave of the H1N1 influenza pandemic could present a host of thorny medical ethics issues best considered well in advance, according to the University of Toronto Joint Centre for Bioethics, which today released nine papers for public discussion.

25 Sep 2009

Liquidia founder Dr. Joseph DeSimone honoured with the NIH Director’s Pioneer Award

Liquidia Technologies today announced its founder, Dr. Joseph DeSimone, has received the National Institutes of Health (NIH) Director’s Pioneer Award. Pioneer Awards are designed to support individual scientists of exceptional creativity who propose pioneering – and possibly transforming – approaches to major challenges in biomedical and behavioral research.

24 Sep 2009

Commitments announced at the Clinton Global Initiative

The second day of the Fifth Annual Meeting of the Clinton Global Initiative (CGI) came to a close with a special session on Northern Ireland, following afternoon plenary and breakout sessions that focused on harnessing innovation for development.

24 Sep 2009

First Edition: September 24, 2009

Today's headlines shed light on developments during the second day of the Finance Committee's health bill mark up.

24 Sep 2009

Regence offers coverage to meet the costs associated with H1N1

To remove financial barriers associated with administration of the H1N1 vaccine and to encourage members to seek vaccination, Regence BlueCross BlueShield will provide coverage for the costs associated with the administration of the H1N1 vaccine during the 2009-2010 flu season, waiving co-pays and deductibles for all members covered by its insured plans. Regence will strongly encourage self-insured employers to cover the full cost to ensure that the greatest number of people are protected.

24 Sep 2009

HPV screening and vaccination programmes could eradicate cervical cancer

Cervical cancer could be eradicated within the next 50 years if countries implement national screening programmes based on detection of the human papilloma virus (HPV), which causes the disease, together with vaccination programmes against the virus, according to a cervical cancer screening expert.

24 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

How the human brain processes incoming sensory signals amidst background noise

The brain never sits idle. Whether we are awake or asleep, watch TV or close our eyes, waves of spontaneous nerve signals wash through our brains. Researchers at the Salk Institute for Biological Studies studying visual attention have discovered a novel mechanism that explains how incoming sensory signals make themselves heard amidst the constant background rumblings so they can be reliably processed and passed on.

24 Sep 2009

Phase III efficacy trial of two AIDS vaccine candidates shows promise

The International AIDS Vaccine Initiative (IAVI) greeted with excitement today’s announcement by the U.S. Military HIV Research Program and the Thai Ministry of Public Health that, according to an initial analysis, a prime-boost combination of two AIDS vaccine candidates has shown partial efficacy in a phase III efficacy trial in Thailand. The prime-boost combination appeared to be about 31% effective at preventing infection with HIV.

24 Sep 2009

CEL-SCI Corporation engages a CRO for clinical trial of its investigational LEAPS-H1N1 treatment

CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment.

24 Sep 2009

It is possible to reduce the risk of HIV infection with a vaccine: AVAC

"Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk of HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show efficacy at preventing HIV. "It will take time and resources to fully analyze, understand and validate the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field as all of us begin the hard work to translate this landmark result into true public health benefit."

24 Sep 2009

Results of Phase III clinical trial of HIV vaccine released

A Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection. According to final results released by the trial sponsor, the U.S. Army Surgeon General, the prime boost combination of ALVAC(R)( )HIV and AIDSVAX(R) B/E( )lowered the rate of HIV infection by 31.2% compared with placebo.

24 Sep 2009

Rescuing immune system cells can reduce risk of prostate cancer

Immune therapies have been explored as a way to treat cancer after it develops. But a new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells.

24 Sep 2009

Pregnant women must be vaccinated against H1N1 and seasonal flu

Pregnant women should be sure to get all their flu shots as soon as the vaccines become available this year to protect them against both the seasonal flu and the H1N1 (swine) flu, according to eight leading national maternal and infant health organizations.

24 Sep 2009

Study of new swine flu vaccines looks for local children to take part

Paediatricians at Bristol Children's Vaccine Centre are looking for 170 children to take part in a study of the two swine 'flu vaccines due to be used in the UK this winter.

23 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

PSI to double its HIV prevention programs

PSI (Population Services International) announced two significant commitments today at the Clinton Global Initiative (CGI): a doubling of its HIV prevention programs that target at-risk men and, in partnership with Procter & Gamble's Children's Safe Drinking Water program, a commitment that will expand the availability of safe drinking water to vulnerable populations across the globe.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009